Niagen Bioscience, Inc. (NASDAQ:NAGE – Get Free Report) has received an average rating of “Buy” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $8.50.
Several analysts have commented on the stock. Canaccord Genuity Group lowered their target price on shares of Niagen Bioscience from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, November 6th. Roth Capital reissued a “buy” rating on shares of Niagen Bioscience in a research note on Wednesday, August 5th. Weiss Ratings lowered Niagen Bioscience from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, November 9th. Finally, Freedom Broker decreased their price objective on Niagen Bioscience from $8.50 to $6.00 and set a “buy” rating on the stock in a report on Friday, November 6th.
View Our Latest Research Report on NAGE
Hedge Funds Weigh In On Niagen Bioscience
Niagen Bioscience Price Performance
Niagen Bioscience stock opened at $2.07 on Friday. Niagen Bioscience has a 12-month low of $2.04 and a 12-month high of $7.11. The stock has a market capitalization of $163.94 million, a P/E ratio of 17.25 and a beta of 2.12. The firm’s 50-day moving average is $2.66 and its two-hundred day moving average is $3.73.
Niagen Bioscience (NASDAQ:NAGE – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported ($0.01) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.01). The business had revenue of $27.19 million during the quarter. Niagen Bioscience had a net margin of 8.37% and a return on equity of 10.18%. As a group, analysts forecast that Niagen Bioscience will post 0.04 EPS for the current year.
About Niagen Bioscience
Niagen Bioscience, Inc. develops and markets products based on nicotinamide riboside (NR), a form of vitamin B3 studied for its role in supporting the body’s production of NAD+. Its offerings include Tru Niagen, a consumer dietary supplement, and Niagen, a branded NR ingredient supplied to other businesses. The company also conducts and supports research on NR, NAD+ and healthy aging. It was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name in 2025. Niagen Bioscience serves consumers and commercial customers in the United States and international markets through online sales, retail and distribution channels.
Further Reading
- Five stocks we like better than Niagen Bioscience
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
